2
Participants
Start Date
November 30, 2009
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
3-4 commercially available antiretroviral drugs
For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
Community Research Initiative of New England, Boston
North Bronx Health Care Network, The Bronx
University of Rochester , Strong Memorial Hospital, Rochester
Whitman Walker Clinic, Washington D.C.
CARE-ID, Annandale
Duke University, Durham
AIDS Research Consortium of Atlanta, Atlanta
Wohlfeiler, Piperato and Associates, LLC, Miami Beach
Therafirst Medical Center, Fort Lauderdale
Gary J. Richmond, MD, PA, Fort Lauderdale
Southwest Infectious Disease, Dallas
North Texas Infectious Disease Consultants, PA, Dallas
DCOL Center, Longview
Therapeutic Concepts, P.A, Houston
Central Texas Clinical Research, Austin
Peter Wolfe, MD, PC, Los Angeles
AIDS Healthcare Foundation Research Center, Beverly Hills
Quest Clinical Research, San Francisco
Kaiser Permanente Immune Deficiency Clinic, Portland
EHS Pulmonary & Critical Care, Spokane
Orlando Immunology Center, Orlando
University of British Columbia,Downtown Infectuous Diseases Clinic, Vancouver
Sunnybrook Health Sciences Centre, Toronto
Clinique médicale l'Actuel,, Montreal
Clinique Médicale Quartier Latin, Montreal
Lead Sponsor
Myrexis Inc.
INDUSTRY